Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 7, 2003. The report details a specific corporate action regarding share re-purchases authorized by shareholders at the Annual General Meeting on May 19, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 500,000 ordinary 25 pence shares.
- Transaction Date: August 6, 2003.
- Price per Share: 1,161.82 pence.
- Purpose: Purchase for cancellation.
Material Changes
The filing does not report material changes in operating results or financial position compared to prior periods. The primary change is the reduction of the company's share capital through the cancellation of 500,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a notification of the share buyback execution.
Investor Verification Points
- Verify the total number of shares authorized for re-purchase at the May 19, 2003 Annual General Meeting to determine remaining capacity.
- Confirm the total cost of the transaction (500,000 shares x 1,161.82 pence) against the company's cash reserves in the most recent full financial report.
- Check subsequent filings to track the cumulative impact of share cancellations on earnings per share (EPS).